bluebird bio (NASDAQ:BLUE)‘s stock had its “buy” rating reissued by equities researchers at Cowen in a research report issued to clients and investors on Friday.
BLUE has been the topic of several other research reports. Cantor Fitzgerald set a $122.00 target price on bluebird bio and gave the company a “sell” rating in a research report on Wednesday, September 5th. BMO Capital Markets reissued a “buy” rating and set a $208.00 target price on shares of bluebird bio in a research report on Friday, August 3rd. Piper Jaffray Companies reissued a “buy” rating on shares of bluebird bio in a research report on Thursday, August 2nd. Maxim Group cut their target price on bluebird bio to $163.00 and set a “hold” rating on the stock in a research report on Monday, July 30th. Finally, Gabelli assumed coverage on bluebird bio in a research report on Thursday, July 12th. They set a “buy” rating and a $239.00 target price on the stock. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $215.00.
NASDAQ:BLUE opened at $132.69 on Friday. bluebird bio has a 1 year low of $102.21 and a 1 year high of $236.17.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($2.90) by $0.17. bluebird bio had a negative return on equity of 33.79% and a negative net margin of 1,326.02%. The business had revenue of $11.50 million for the quarter, compared to the consensus estimate of $6.90 million. During the same quarter in the previous year, the company posted ($1.73) EPS. The company’s revenue was up 49.2% compared to the same quarter last year. On average, sell-side analysts predict that bluebird bio will post -10.85 EPS for the current year.
In related news, insider Philip D. Gregory sold 1,800 shares of the business’s stock in a transaction on Friday, October 5th. The stock was sold at an average price of $140.56, for a total transaction of $253,008.00. Following the completion of the transaction, the insider now owns 32,471 shares in the company, valued at approximately $4,564,123.76. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jeffrey T. Walsh sold 1,500 shares of the business’s stock in a transaction on Friday, August 10th. The shares were sold at an average price of $156.93, for a total value of $235,395.00. Following the transaction, the insider now owns 36,995 shares of the company’s stock, valued at approximately $5,805,625.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,359 shares of company stock valued at $6,761,176. 3.00% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. CIBC Asset Management Inc boosted its holdings in bluebird bio by 28.5% during the 2nd quarter. CIBC Asset Management Inc now owns 1,780 shares of the biotechnology company’s stock valued at $279,000 after acquiring an additional 395 shares during the period. State of Alaska Department of Revenue boosted its holdings in bluebird bio by 9.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,320 shares of the biotechnology company’s stock valued at $922,000 after acquiring an additional 530 shares during the period. Dynamic Technology Lab Private Ltd boosted its holdings in bluebird bio by 43.2% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 2,040 shares of the biotechnology company’s stock valued at $320,000 after acquiring an additional 615 shares during the period. Aperio Group LLC boosted its holdings in bluebird bio by 9.7% during the 2nd quarter. Aperio Group LLC now owns 7,295 shares of the biotechnology company’s stock valued at $1,145,000 after acquiring an additional 646 shares during the period. Finally, Stratos Wealth Partners LTD. purchased a new stake in shares of bluebird bio in the 3rd quarter worth $106,000. Institutional investors own 98.25% of the company’s stock.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Featured Story: Using the New Google Finance Tool
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.